Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03850912 · ClinicalTrials.gov registry record · NA
Symptom Management Implementation of Patient Reported Outcomes in Oncology
A NA study, sponsored by Dana-Farber Cancer Institute.
- Completed
- Registry status
- NA
- Development phase
- 42,808
- Enrollment target
NCT03850912 is a NA study that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 42,808 participants.
The verdict
NCT03850912, a NA study, has completed, sponsored by Dana-Farber Cancer Institute.
- COMPLETED
- Registry status
- NA
- Development phase
- 42,808 participants
- Enrollment target
Study Summary
Deficits in the management of common symptoms cause substantial morbidity for cancer patients.Because the health care delivery system is structured to be reactive and not proactive, there are missed opportunities to optimize symptom control. Growth in Internet access and proliferation of smartphones has created an opportunity to re-engineer cancer care delivery. Electronic symptom tracking and feedback is a promising strategy to improve symptom control. Electronic patient reported outcome (ePRO) monitoring of cancer symptoms has been shown to decrease symptom burden, improve quality of life, reduce acute care and even extend survival. SIMPRO will use functioning ePRO prototypes to create and refine the electronic symptom management system eSyM
Interventions
- OTHER Qualitative Interview
- OTHER Stakeholder Survey (Control Period)
- OTHER Stakeholder Survey (Intervention Period)
- OTHER SASS Questionnaire
- OTHER eSyM
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42,808 participants |
| Start Date | 2019-07-25 |
| Est. Completion | 2025-06-09 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03850912
The ClinicalTrials.gov registry entry for NCT03850912 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 42,808 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Qualitative Interview is the first listed.
NCT03850912 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03850912 about?
NCT03850912 is a clinical study titled "Symptom Management Implementation of Patient Reported Outcomes in Oncology". Deficits in the management of common symptoms cause substantial morbidity for cancer patients.Because the health care delivery system is structured to be reactive and not proactive, there are missed opportunities to optimize symptom control. Growth in Internet access and proliferation of smartphones...
What is the current status of trial NCT03850912?
This trial is currently completed. It is a NA study. The enrollment target is 42,808 participants. The study started on 2019-07-25. Estimated completion is 2025-06-09.
What interventions are being tested in trial NCT03850912?
The interventions under investigation include: Qualitative Interview (OTHER), Stakeholder Survey (Control Period) (OTHER), Stakeholder Survey (Intervention Period) (OTHER), SASS Questionnaire (OTHER), eSyM (OTHER).
Who is sponsoring clinical trial NCT03850912?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.